| Biomarker ID | 133 |
| PMID | 17764114 |
| Year | 2008 |
| Biomarker | PTGS2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Other |
| Source | Serum |
| Subjects | Humans |
| Regulation | Increased expression with increase in relapse |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Selenium pathway, C-Myb transcription factor network,VEGF signaling pathway,Leishmaniasis,Prostaglandin biosynthesis and regulation |
| Experiment | Biochemical Recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Out of 124 patients who had prostate cancer and followed up within a period of 72 months, 24 suffered from relapse. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.0395 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PTGS2 |